<HashMap><database>biostudies-literature</database><scores/><additional><submitter>Saville NM</submitter><funding>UK Medical Research Council (MRC)/ Newton Fund</funding><pagination>e064709</pagination><full_dataset_link>https://www.ebi.ac.uk/biostudies/studies/S-EPMC9936277</full_dataset_link><repository>biostudies-literature</repository><omics_type>Unknown</omics_type><volume>13(2)</volume><pubmed_abstract>&lt;h4>Introduction&lt;/h4>Despite evidence that iron and folic acid (IFA) supplements can improve anaemia in pregnant women, uptake in Nepal is suboptimal. We hypothesised that providing virtual counselling twice in mid-pregnancy, would increase compliance to IFA tablets during the COVID-19 pandemic compared with antenatal care (ANC alone.&lt;h4>Methods and analysis&lt;/h4>This non-blinded individually randomised controlled trial in the plains of Nepal has two study arms: (1) control: routine ANC; and (2) 'Virtual' antenatal counselling plus routine ANC. Pregnant women are eligible to enrol if they are married, aged 13-49 years, able to respond to questions, 12-28 weeks' gestation, and plan to reside in Nepal for the next 5 weeks. The intervention comprises two virtual counselling sessions facilitated by auxiliary nurse midwives at least 2 weeks apart in mid-pregnancy. Virtual counselling uses a dialogical problem-solving approach with pregnant women and their families. We randomised 150 pregnant women to each arm, stratifying by primigravida/multigravida and IFA consumption at baseline, providing 80% power to detect a 15% absolute difference in primary outcome assuming 67% prevalence in control arm and 10% loss-to-follow-up. Outcomes are measured 49-70 days after enrolment, or up to delivery otherwise.&lt;h4>Primary outcome&lt;/h4>consumption of IFA on at least 80% of the previous 14 days.&lt;h4>Secondary outcomes&lt;/h4>dietary diversity, consumption of intervention-promoted foods, practicing ways to enhance bioavailability and knowledge of iron-rich foods. Our mixed-methods process evaluation explores acceptability, fidelity, feasibility, coverage (equity and reach), sustainability and pathways to impact. We estimate costs and cost-effectiveness of the intervention from a provider perspective. Primary analysis is by intention-to-treat, using logistic regression.&lt;h4>Ethics and dissemination&lt;/h4>We obtained ethical approval from Nepal Health Research Council (570/2021) and UCL ethics committee (14301/001). We will disseminate findings in peer-reviewed journal articles and by engaging policymakers in Nepal.&lt;h4>Trial registration number&lt;/h4>ISRCTN17842200.</pubmed_abstract><journal>BMJ open</journal><pubmed_title>Study protocol for a randomised controlled trial of a virtual antenatal intervention for improved diet and iron intake in Kapilvastu district, Nepal: VALID.</pubmed_title><pmcid>PMC9936277</pmcid><funding_grant_id>MR/R020485/1</funding_grant_id><pubmed_authors>Morrison J</pubmed_authors><pubmed_authors>Copas A</pubmed_authors><pubmed_authors>Harris-Fry H</pubmed_authors><pubmed_authors>Haghparast-Bidgoli H</pubmed_authors><pubmed_authors>Arjyal A</pubmed_authors><pubmed_authors>Bhattarai S</pubmed_authors><pubmed_authors>Baral SC</pubmed_authors><pubmed_authors>Hillman S</pubmed_authors><pubmed_authors>Saville NM</pubmed_authors><pubmed_authors>Giri S</pubmed_authors><pubmed_authors>Manandhar S</pubmed_authors><pubmed_authors>Thapaliya B</pubmed_authors></additional><is_claimable>false</is_claimable><name>Study protocol for a randomised controlled trial of a virtual antenatal intervention for improved diet and iron intake in Kapilvastu district, Nepal: VALID.</name><description>&lt;h4>Introduction&lt;/h4>Despite evidence that iron and folic acid (IFA) supplements can improve anaemia in pregnant women, uptake in Nepal is suboptimal. We hypothesised that providing virtual counselling twice in mid-pregnancy, would increase compliance to IFA tablets during the COVID-19 pandemic compared with antenatal care (ANC alone.&lt;h4>Methods and analysis&lt;/h4>This non-blinded individually randomised controlled trial in the plains of Nepal has two study arms: (1) control: routine ANC; and (2) 'Virtual' antenatal counselling plus routine ANC. Pregnant women are eligible to enrol if they are married, aged 13-49 years, able to respond to questions, 12-28 weeks' gestation, and plan to reside in Nepal for the next 5 weeks. The intervention comprises two virtual counselling sessions facilitated by auxiliary nurse midwives at least 2 weeks apart in mid-pregnancy. Virtual counselling uses a dialogical problem-solving approach with pregnant women and their families. We randomised 150 pregnant women to each arm, stratifying by primigravida/multigravida and IFA consumption at baseline, providing 80% power to detect a 15% absolute difference in primary outcome assuming 67% prevalence in control arm and 10% loss-to-follow-up. Outcomes are measured 49-70 days after enrolment, or up to delivery otherwise.&lt;h4>Primary outcome&lt;/h4>consumption of IFA on at least 80% of the previous 14 days.&lt;h4>Secondary outcomes&lt;/h4>dietary diversity, consumption of intervention-promoted foods, practicing ways to enhance bioavailability and knowledge of iron-rich foods. Our mixed-methods process evaluation explores acceptability, fidelity, feasibility, coverage (equity and reach), sustainability and pathways to impact. We estimate costs and cost-effectiveness of the intervention from a provider perspective. Primary analysis is by intention-to-treat, using logistic regression.&lt;h4>Ethics and dissemination&lt;/h4>We obtained ethical approval from Nepal Health Research Council (570/2021) and UCL ethics committee (14301/001). We will disseminate findings in peer-reviewed journal articles and by engaging policymakers in Nepal.&lt;h4>Trial registration number&lt;/h4>ISRCTN17842200.</description><dates><release>2023-01-01T00:00:00Z</release><publication>2023 Feb</publication><modification>2024-10-18T18:20:36.158Z</modification><creation>2024-10-18T18:20:36.158Z</creation></dates><accession>S-EPMC9936277</accession><cross_references><pubmed>36797013</pubmed><doi>10.1136/bmjopen-2022-064709</doi></cross_references></HashMap>